Chemogef 250mg Tablet

About

Chemogef 250mg Tablet is an oral targeted therapy belonging to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. It functions by selectively blocking the activity of the EGFR, a protein found on the surface of many cancer cells that plays a crucial role in cell growth and division. By inhibiting EGFR signaling, Chemogef helps to prevent the proliferation of cancer cells and can induce apoptosis (programmed cell death). This targeted approach is particularly effective in treating certain types of cancers that have specific EGFR mutations, offering a personalized treatment option. It is often utilized in advanced or metastatic settings where its precise mechanism can lead to significant clinical benefits, including improved response rates and disease control, especially in patients who have previously failed other therapies.

Uses

• Treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations
• Management of advanced or metastatic NSCLC
• Second-line therapy for NSCLC after platinum-based chemotherapy
• Treatment of certain other solid tumors with EGFR overexpression

Directions For Use

Take this tablet orally, usually once daily, at least one hour before or two hours after food. Swallow the tablet whole with water.

Benefits

• Targets specific EGFR mutations
• Oral administration for convenience
• Improved response rates in sensitive tumors
• Potential for prolonged progression-free survival
• Reduced tumor burden
• Better tolerability compared to conventional chemotherapy

Side Effects

• Skin rash (acneiform dermatitis)
• Diarrhea
• Dry skin
• Nausea
• Vomiting
• Fatigue
• Stomatitis (mouth sores)
• Elevated liver enzymes
• Interstitial lung disease (rare but serious)
• Ocular toxicity (e.g., dry eyes)
• Nail changes
• Anorexia

Safety Measures

• Alcohol - Limit alcohol intake as it may exacerbate liver enzyme elevations and gastrointestinal side effects.
• Pregnancy - Chemogef is not recommended during pregnancy due to potential harm to the fetus. Women of childbearing potential should use effective contraception.
• Breastfeeding - Breastfeeding should be avoided during treatment with Chemogef as it is unknown if the drug is excreted in human milk and could be harmful to the infant.
• Liver - Use with caution in patients with hepatic impairment. Regular monitoring of liver function tests is essential, and dose adjustments may be required.
• Kidney - Generally, no dose adjustment is needed for mild to moderate renal impairment. Use with caution in severe renal dysfunction.
• Lung - Patients should be monitored for symptoms of interstitial lung disease (ILD), such as acute onset or worsening of dyspnea, cough, and fever.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.